Drugs show efficacy in patients with type 2 diabetes, ESRD

02/1/2013 | Renal and Urology News

Sitagliptin therapy led to a 0.72% reduction in mean A1C levels at 54 weeks, while glipizide treatment resulted in an 0.87% decrease among type 2 diabetes patients with end-stage renal disease who require dialysis, according to a study in the American Journal of Kidney Diseases. Researchers also found the incidence rates of symptomatic hypoglycemia were 6.3% in the sitagliptin group and 10.8% in the glipizide group.

View Full Article in:

Renal and Urology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA